St. Johns Investment Management Company LLC Has $1.51 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

St. Johns Investment Management Company LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 0.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 9,543 shares of the company’s stock after selling 90 shares during the period. St. Johns Investment Management Company LLC’s holdings in Johnson & Johnson were worth $1,510,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Keener Financial Planning LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth $40,000. WFA Asset Management Corp boosted its position in shares of Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth $44,000. Disciplined Equity Management Inc. bought a new position in shares of Johnson & Johnson in the 4th quarter worth $45,000. Finally, Grayhawk Investment Strategies Inc. lifted its holdings in Johnson & Johnson by 528.6% during the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after acquiring an additional 259 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on JNJ. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Thursday, June 20th. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 22nd. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Bank of America reduced their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Finally, The Goldman Sachs Group assumed coverage on Johnson & Johnson in a report on Thursday, May 30th. They set a “neutral” rating and a $160.00 target price on the stock. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $174.07.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $146.81 on Thursday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The stock’s 50-day simple moving average is $148.13 and its 200 day simple moving average is $154.24. The company has a market cap of $353.32 billion, a P/E ratio of 9.15, a P/E/G ratio of 2.45 and a beta of 0.53. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. Johnson & Johnson’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.68 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.63 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a $1.24 dividend. The ex-dividend date was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.